Stimulant medication and symptom interrelations in children, adolescents and adults with attention-deficit/hyperactivity disorder.

IF 6 2区 医学 Q1 PEDIATRICS
Zarah van der Pal, Hilde M Geurts, Jonas M B Haslbeck, Alex van Keeken, Anne Marijn Bruijn, Linda Douw, Daan van Rooij, Barbara Franke, Jan Buitelaar, Nanda Lambregts-Rommelse, Catharina Hartman, Jaap Oosterlaan, Marjolein Luman, Liesbeth Reneman, Pieter J Hoekstra, Tessa F Blanken, Anouk Schrantee
{"title":"Stimulant medication and symptom interrelations in children, adolescents and adults with attention-deficit/hyperactivity disorder.","authors":"Zarah van der Pal, Hilde M Geurts, Jonas M B Haslbeck, Alex van Keeken, Anne Marijn Bruijn, Linda Douw, Daan van Rooij, Barbara Franke, Jan Buitelaar, Nanda Lambregts-Rommelse, Catharina Hartman, Jaap Oosterlaan, Marjolein Luman, Liesbeth Reneman, Pieter J Hoekstra, Tessa F Blanken, Anouk Schrantee","doi":"10.1007/s00787-024-02610-8","DOIUrl":null,"url":null,"abstract":"<p><p>Stimulant medication is effective in alleviating overall symptom severity of attention-deficit/hyperactivity disorder (ADHD), yet interindividual variability in treatment response and tolerability still exists. While network analysis has identified differences in ADHD symptom relations, the impact of stimulant medication remains unexplored. Increased understanding of this association could provide valuable insights for optimizing treatment approaches for individuals with ADHD. In this study, we compared and characterized ADHD symptom networks (including 18 ADHD symptoms) between stimulant-treated (n = 348) and untreated (n = 70) individuals with ADHD and non-ADHD controls (NACs; n = 444). Moreover, we compared symptom networks between subgroups defined by their stimulant treatment trajectory (early-and-intense use, late-and-moderate use). Stimulant-treated individuals with ADHD showed stronger associations between symptoms, compared with untreated individuals with ADHD and NACs. We found no differences in symptom networks between the stimulant treatment trajectory subgroups. Prospective longitudinal studies are needed to disentangle whether the identified differences stem from treatment or pre-existing factors.</p>","PeriodicalId":11856,"journal":{"name":"European Child & Adolescent Psychiatry","volume":" ","pages":""},"PeriodicalIF":6.0000,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Child & Adolescent Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00787-024-02610-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0

Abstract

Stimulant medication is effective in alleviating overall symptom severity of attention-deficit/hyperactivity disorder (ADHD), yet interindividual variability in treatment response and tolerability still exists. While network analysis has identified differences in ADHD symptom relations, the impact of stimulant medication remains unexplored. Increased understanding of this association could provide valuable insights for optimizing treatment approaches for individuals with ADHD. In this study, we compared and characterized ADHD symptom networks (including 18 ADHD symptoms) between stimulant-treated (n = 348) and untreated (n = 70) individuals with ADHD and non-ADHD controls (NACs; n = 444). Moreover, we compared symptom networks between subgroups defined by their stimulant treatment trajectory (early-and-intense use, late-and-moderate use). Stimulant-treated individuals with ADHD showed stronger associations between symptoms, compared with untreated individuals with ADHD and NACs. We found no differences in symptom networks between the stimulant treatment trajectory subgroups. Prospective longitudinal studies are needed to disentangle whether the identified differences stem from treatment or pre-existing factors.

患有注意力缺陷/多动症的儿童、青少年和成人的兴奋剂药物治疗与症状之间的相互关系。
兴奋剂药物能有效减轻注意力缺陷/多动障碍(ADHD)的总体症状严重程度,但治疗反应和耐受性方面的个体差异仍然存在。虽然网络分析发现了注意力缺陷/多动障碍症状关系的差异,但兴奋剂药物的影响仍未得到探讨。加深对这一关联的了解,可以为优化多动症患者的治疗方法提供有价值的见解。在这项研究中,我们比较并描述了接受过兴奋剂治疗(348 人)和未接受过兴奋剂治疗(70 人)的多动症患者与非多动症对照组(444 人)之间的多动症症状网络(包括 18 种多动症症状)。此外,我们还比较了根据兴奋剂治疗轨迹(早期和密集使用、晚期和中度使用)定义的亚组之间的症状网络。与未经治疗的 ADHD 患者和 NACs 相比,接受过兴奋剂治疗的 ADHD 患者症状之间的关联性更强。我们发现,兴奋剂治疗轨迹亚组之间的症状网络没有差异。我们需要进行前瞻性纵向研究,以厘清所发现的差异是源于治疗还是原有因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
12.80
自引率
4.70%
发文量
186
审稿时长
6-12 weeks
期刊介绍: European Child and Adolescent Psychiatry is Europe''s only peer-reviewed journal entirely devoted to child and adolescent psychiatry. It aims to further a broad understanding of psychopathology in children and adolescents. Empirical research is its foundation, and clinical relevance is its hallmark. European Child and Adolescent Psychiatry welcomes in particular papers covering neuropsychiatry, cognitive neuroscience, genetics, neuroimaging, pharmacology, and related fields of interest. Contributions are encouraged from all around the world.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信